Literature DB >> 31282534

Immune Activation and Inflammation in People With Human Immunodeficiency Virus: Challenging Targets.

Netanya S Utay1, Edgar T Overton2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31282534      PMCID： PMC7184903          DOI： 10.1093/infdis/jiz351

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  42 in total

1.  CD4⁺CD73⁺ T cells are associated with lower T-cell activation and C reactive protein levels and are depleted in HIV-1 infection regardless of viral suppression.

Authors:  Patrick J Schuler; Bernard J C Macatangay; Zenichiro Saze; Edwin K Jackson; Sharon A Riddler; William G Buchanan; Benedict B Hilldorfer; John W Mellors; Theresa L Whiteside; Charles R Rinaldo
Journal:  AIDS       Date:  2013-06-19       Impact factor: 4.177

2.  Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders.

Authors:  Stefania Piconi; Serena Parisotto; Giuliano Rizzardini; Simone Passerini; Roberta Terzi; Barbara Argenteri; Paola Meraviglia; Amedeo Capetti; Mara Biasin; Daria Trabattoni; Mario Clerici
Journal:  Blood       Date:  2011-05-16       Impact factor: 22.113

3.  Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells.

Authors:  Michael M Lederman; Leonard Calabrese; Nicholas T Funderburg; Brian Clagett; Kathy Medvik; Hector Bonilla; Barbara Gripshover; Robert A Salata; Alan Taege; Michelle Lisgaris; Grace A McComsey; Elizabeth Kirchner; Jane Baum; Carey Shive; Robert Asaad; Robert C Kalayjian; Scott F Sieg; Benigno Rodriguez
Journal:  J Infect Dis       Date:  2011-10-15       Impact factor: 5.226

4.  Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy.

Authors:  Peter W Hunt; Jeffrey N Martin; Elizabeth Sinclair; Lorrie Epling; Juli Teague; Mark A Jacobson; Russell P Tracy; Lawrence Corey; Steven G Deeks
Journal:  J Infect Dis       Date:  2011-05-15       Impact factor: 5.226

5.  Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy.

Authors:  Nicholas T Funderburg; Ying Jiang; Sara M Debanne; Danielle Labbato; Steven Juchnowski; Brian Ferrari; Brian Clagett; Janet Robinson; Michael M Lederman; Grace A McComsey
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-01       Impact factor: 3.731

6.  Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286.

Authors:  Allan R Tenorio; Ellen S Chan; Ronald J Bosch; Bernard J C Macatangay; Sarah W Read; Suria Yesmin; Babafemi Taiwo; David M Margolis; Jeffrey M Jacobson; Alan L Landay; Cara C Wilson
Journal:  J Infect Dis       Date:  2014-09-11       Impact factor: 5.226

7.  Microbial translocation is a cause of systemic immune activation in chronic HIV infection.

Authors:  Jason M Brenchley; David A Price; Timothy W Schacker; Tedi E Asher; Guido Silvestri; Srinivas Rao; Zachary Kazzaz; Ethan Bornstein; Olivier Lambotte; Daniel Altmann; Bruce R Blazar; Benigno Rodriguez; Leia Teixeira-Johnson; Alan Landay; Jeffrey N Martin; Frederick M Hecht; Louis J Picker; Michael M Lederman; Steven G Deeks; Daniel C Douek
Journal:  Nat Med       Date:  2006-11-19       Impact factor: 53.440

8.  The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial.

Authors:  Ma Somsouk; Richard M Dunham; Michelle Cohen; Rebecca Albright; Mohamed Abdel-Mohsen; Teri Liegler; Jeffrey Lifson; Michael Piatak; Robert Gorelick; Yong Huang; Yuaner Wu; Priscilla Y Hsue; Jeffrey N Martin; Steven G Deeks; Joseph M McCune; Peter W Hunt
Journal:  PLoS One       Date:  2014-12-29       Impact factor: 3.240

9.  Immune activation and HIV-specific T cell responses are modulated by a cyclooxygenase-2 inhibitor in untreated HIV-infected individuals: An exploratory clinical trial.

Authors:  Christian Prebensen; Marius Trøseid; Thor Ueland; Anders Dahm; Per Morten Sandset; Ingeborg Aaberge; Kristian Waalen; Anne Ma Dyrhol-Riise; Kjetil Taskén; Dag Kvale
Journal:  PLoS One       Date:  2017-05-02       Impact factor: 3.240

10.  Serum Bovine Immunoglobulins Improve Inflammation and Gut Barrier Function in Persons with HIV and Enteropathy on Suppressive ART.

Authors:  Netanya S Utay; Anoma Somasunderam; John E Hinkle; Bryon W Petschow; Christopher J Detzel; Ma Somsouk; Carl J Fichtenbaum; Eric M Weaver; Audrey L Shaw; David M Asmuth
Journal:  Pathog Immun       Date:  2019-05-03
View more
  1 in total

1.  Evaluation of Six Weekly Oral Fecal Microbiota Transplants in People with HIV.

Authors:  Netanya S Utay; Ana N Monczor; Anoma Somasunderam; Sofia Lupo; Zhi-Dong Jiang; Ashley S Alexander; Malcolm Finkelman; Karen J Vigil; Jordan E Lake; Blake Hanson; Herbert L DuPont; Roberto C Arduino
Journal:  Pathog Immun       Date:  2020-12-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.